Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 1 TO FORM S-1 - REATA PHARMACEUTICALS INC | d84883ds1a.htm |
| EX-5.1 - EX-5.1 - REATA PHARMACEUTICALS INC | d84883dex51.htm |
| EX-4.1 - EX-4.1 - REATA PHARMACEUTICALS INC | d84883dex41.htm |
| EX-3.2 - EX-3.2 - REATA PHARMACEUTICALS INC | d84883dex32.htm |
| EX-1.1 - EX-1.1 - REATA PHARMACEUTICALS INC | d84883dex11.htm |
| EX-3.4 - EX-3.4 - REATA PHARMACEUTICALS INC | d84883dex34.htm |
| EX-3.5 - EX-3.5 - REATA PHARMACEUTICALS INC | d84883dex35.htm |
| EX-10.13 - EX-10.13 - REATA PHARMACEUTICALS INC | d84883dex1013.htm |
| EX-10.12 - EX-10.12 - REATA PHARMACEUTICALS INC | d84883dex1012.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated February 8, 2016, in Amendment No.1 to the Registration Statement (Form S-1 No. 333-208843) and related Prospectus of Reata Pharmaceuticals, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
Dallas, Texas
February 8, 2016